Overcoming Translational Hurdles, Improving Immunology Assays & Optimizing Clinical Strategies for Mitigating Adverse Immune Responses
The 3rd Annual Gene Therapy Immunogenicity Summit is industry’s definitive forum enabling you to better modulate, measure and predict the immune response to your gene therapy candidate.
In the context of ever-increasing gene therapy clinical activity and uncertainty around challenges posed by immune responses to delivery, this summit will unite large pharma and innovative biotech’s to ensure that you’re up to speed on the latest approaches to evaluate and overcome pre-existing immunity to AAV vectors, understand how immune-modulatory strategies can help to ensure efficacy and safety and learn the reality of regulatory expectations around immunological assays.
Incorporating insights from leading immunological, bioanalytical, and translational experts, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing clinical mitigation strategies to address immunogenicity.
With 35+ industry-based speakers covering pre-clinical and clinical immunogenicity challenges over 2 tracks and 3 packed days of content, don’t miss your chance to join over 100+ fellow industry experts to network in person and share your research as you seek new and improved ways of predicting immunogenicity in the clinic to ultimately ensure the safety and efficacy of gene therapies.
2 Dedicated New Tracks of Content Seen in 2022:
Uncover novel in-vivo models, explore immune profiling methodologies, and better understand cellular immunity in the non-clinical setting by hearing from Spirovant, Spark Therapeutics, Indiana University, Amarna, Roche and more
Better monitor and modulate immunogenicity in the clinic, examine the effects of administration route and uncover the role of complement by hearing from Rocket Pharma, Prevail Therapeutics, Beam Therapeautics, Adverum, Ask Bio and more
2022 World-Class Speaker Faculty Included
Senior Director - Therapeutics Discovery
Head Translational Science
Associate Director - Bioanalytical Development
VP clinical development
Chief Executive Officer
What Previous Attendees Thought of the Summit?
“The Gene Therapy Immunogenicity Summit is once again an extremely important venue for all new discoveries in Immunogenicity relating to Gene Therapy”
Head of Bioanalytical Assay Development, Adverum
“I really appreciate that the organizer put together a strong program with a list of experts in the field, and covered several important areas of AAV immunogenicity that are critical for development of AAV based gene therapy products”
Associate Director, Precision Bio
“The focus on immunogenicity in gene therapy, covering mechanism, methods to prevent it, and assays to monitor it was very timely and helpful”
Director Translational Medicine, Tenaya